<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550795</url>
  </required_header>
  <id_info>
    <org_study_id>Breast PONV</org_study_id>
    <secondary_id>GCIRB2014</secondary_id>
    <nct_id>NCT02550795</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer</brief_title>
  <official_title>Effects of Single Dose Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous reports demonstrated that dexmedetomidine could reduce the incidence of
      postoperative nausea and vomiting (PONV). Dexamethason also had been commonly used for
      ajuvant drugs for preventing and reducing PONV. So investigator want to study about the
      effect of dexmedetomidine only or combined with dexamethasone for preventing PONV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous reports demonstrated that dexmedetomidine, a alpha 2 selective agonist could reduce
      the incidence of postoperative nausea and vomiting (PONV). Dexamethason also had been
      commonly used for ajuvant drugs for preventing and reducing PONV. So investigator want to
      study about the effect of dexmedetomidine only or combined with dexamethasone for preventing
      PONV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative nausea (visual analogue scale for nausea)</measure>
    <time_frame>Changes from baseline in postoperative nausea at 30 min</time_frame>
    <description>visual analogue scale for postoperative nausea (unit on a scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative vomiting (number of participants with vomiting)</measure>
    <time_frame>Changes from baseline in postoperative nausea at 30 min</time_frame>
    <description>frequencies of vomiting (number of participants with vomiting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting (Rhodes index score)</measure>
    <time_frame>6hour and 24 hour after operative end</time_frame>
    <description>Rhodes index for PONV and Retching (Rhodes index score)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of 0.9% normal saline 10ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of 0.5ug/kg of dexmedetomidine (5ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine and dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>administration of dexmedetomidine only</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>DO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine and dexamethasone</intervention_name>
    <description>administration of dexmedetomidine and dexamethasone</description>
    <arm_group_label>Dexmedetomidine and dexamethasone</arm_group_label>
    <other_name>DD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>administration of normal saline</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>OO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA Physical status I or II female scheduled for breast conserving surgery of modified
             radical mastectomy.

        Exclusion Criteria:

          -  uncontrolled cardiovascular disease

          -  history of chronic pain

          -  smoker

          -  previous history of steroid administraion

          -  neoajuvant chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Youn Yi Jo</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

